New dosing strategy for schizophrenia drug aims to cut side effects

NCT ID NCT06821945

Recruiting now Disease control Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests different ways to start taking olanzapine, a common schizophrenia medication, to see if a slower dose increase can reduce side effects while still controlling symptoms. About 120 adults with schizophrenia will receive one of several dosing schedules or a placebo. The goal is to find a safer, effective starting plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olanzapine
What this could lead to: If successful, this could lead to a safer way to start olanzapine treatment for schizophrenia, reducing side effects while still controlling symptoms.
What could go wrong: This is an early phase 2 trial with only 120 participants, so results may not apply to everyone. Different dosing schedules may not improve safety or effectiveness as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Hanyang University Guri Hospital
NOT_YET_RECRUITING

Guri-si, South Korea
Kyungbook National university hospital
RECRUITING

Daegu, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.